Mikhail Blagosklonny Helps Make Cancer Better

Not many people would think that a treatment that is normally used by cosmetic surgeons would be something that oncologists would be able to use but Mikhail Blagosklonny was able to use it for some of his patients to make their lives better and to provide them with a solution to a problem with their immunity. He did all of this to ensure that he could help them and to show them that there are more cancer treatment options available so that they will be able to get the best experience possible with their cancer disease.Mikhail Blagosklonny has always known that there are more treatment options for people who are dealing with cancer, he just had to work hard to be able to figure out what they were going to be and how he would be able to use them. It made more sense for Mikhail Blagosklonny to be studying these things because he is a cancer doctor. As an oncologist, he is dedicated to being able to help people who have the disease and give them all of the opportunities that they need to truly start healing no matter what is going on with their treatment options.

Because Mikhail Blagosklonny started Oncotarget, he has been able to learn about this and other treatment options. This publication that he has allows him the chance to find information out about unconventional treatment methods. He can learn the right way to treat cancer and how it can be beneficial to patients who are in different stages of treatment. This lates rejuvenation therapy for immunity is just another in a lineup of things that Mikhail Blagosklonny has been able to do. he wants to make sure that he can help people and the commitment that he has to his practice is demonstrative of it.While Mikhail Blagosklonny has always been doing things like this, he knows that he is only able to learn what he can because of Oncotarget. In the publication, people can talk with each other about the different treatments they have in their practices. They can also learn from other specialists.

There is no other publication that allows doctors to connect on that level while they are learning the different things about other practices. It is something that has allowed him to learn more and to experience more with the practice that he has and the opportunities that he is able to give other people.Since the Oncotarget publication has taken off, other doctors are able to help each other. While it was originally intended for people who were practicing cancer treatment, it is now something that is going to be able to help people who have different practice areas. Mikhail Blagosklonny’s Oncotarget is dedicated to helping people and giving them the best experience possible no matter what is going on with their treatment or the other things that they are doing in their lives. He wants to make all different type of specialists have easier access to the care and treatment they deserve.

Bringing Light to Life Through Clay Siegall

Seattle Genetics is a biotech company located in Bothell, Washington. They have gained widespread interest for their research and current uses for the drug called ADCETRIS. They recently have announced an increase in their public stock offering from $480 million to an astounding $552 million without showing a profit. The company has made it clear that building the business is far more important than showing an immediate profit. It also helps that they will be expanding the uses of the drug ADCETRIS well beyond just cancer treatments in the near future. They are forecasting increasing their staff from the current count of over 800 employees to approximately 1300 by the year 2020. Dr. Clay Siegall has played a huge part in leading the Seattle Genetics’ initial public offering in 2001 by implementing capital-raising activities and securing more than $1.2 billion through public and private financings.

Dr. Clay B. Siegall, Ph.D. is the the CEO, President, Chief Executive Officer and Chairman of the Board of Seattle Genetics, Inc. He has an extensive background in biotechnology and has worked with research companies, as well as Alder BioPharmaceuticals and Mirna Therapeutics where he actively serves on the board of directors for both companies. Dr. Siegall has spent his lifetime studying science and then researching ways to improve people’s health who are suffering from life altering diseases. He earned a B.S. degree in Zoology from the University of Maryland and then furthered his studies to later earn his Ph.D. in Genetics from George Washington University located in Washington, DC.

Dr. Siegall was the key player in securing the 2011 FDA approval of its first ADC product, ADCETRIS. Which is now approved and available in over 60 countries worldwide, making it a global brand. This has opened the door for advancing a pipeline of proprietary ADCs for the treatment of cancer. He has received a variety of awards which include the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. He currently holds 15 patents and has written more than 70 publications.